Research progress on myeloid-derived suppressor cell and transplantation immune tolerance
-
摘要: 髓源性抑制细胞（MDSC）是骨髓来源的一类异质性细胞群，最早在肿瘤中被发现，能够抑制T细胞的功能，具有免疫抑制作用。近年来越来越多的研究表明，在器官移植领域，MDSC对宿主的免疫功能也具有调节作用，能够诱导特异性免疫耐受，对移植器官发挥保护作用，有望成为临床上治疗移植排斥反应的新靶点。本文就MDSC的生物学特性和MDSC诱导免疫耐受的机制进行综述。
-
关键词:
- 髓源性抑制细胞 /
- 免疫耐受 /
- 器官移植 /
- 排斥反应 /
- 移植免疫 /
- 调节性T细胞（Treg） /
- 诱导型一氧化氮合酶 /
- 程序性细胞死亡受体-1（PD-1）
Abstract: Myeloid-derived suppressor cell (MDSC) is a type of heterogeneous cell derived from bone marrow, which was first found in tumor. MDSC can inhibit the function of T cell with immunosuppressive effect. In recent years, more and more studies have shown that in the field of organ transplantation, MDSC can also regulate the host's immune function, induce specific immune tolerance, and play a protective role in transplant organs, which is expected to become a new target in clinical treatment of transplant rejection. The biological characteristics of MDSC and the mechanism of immune tolerance induced by MDSC were reviewed in this paper. -
图 2 MDSC诱导移植免疫耐受的机制
Figure 2. Mechanism of transplantation immune tolerance induced by MDSC
表 1 MDSC在器官移植免疫耐受中的作用的相关文献
Table 1. The relative literatures about the role of MDSC in immune tolerance of organ transplantation
作者 年份 种属 器官 小分子物质 干预措施 结论 Dugast, et al[17] 2008 大鼠 肾脏 iNOS 抗CD28抗体 抗CD28抗原诱导iNOS-MDSC分化，诱导移植免疫耐受 Zhang, et al[18] 2008 小鼠 皮肤 精氨酸酶 ILT2①抑制性受体 注射MDSC可延长移植皮肤存活时间 Garcia, et al[19] 2010 小鼠 心脏 iNOS、精氨酸酶 抗CD40抗体 MDSC在移植物内聚集，诱导Treg分化 Turnquist, et al[20] 2011 小鼠 心脏 iNOS、精氨酸酶 IL-33 IL-33诱导MDSC分化，但其不能延长移植物存活时间 Adeegbe, et al[21] 2011 小鼠 皮肤 —② G-CSF、IL-2 MDSC和Treg协同作用，同种异体T细胞反应活性降低 Chen, et al [22] 2012 小鼠 心脏 IDO③ ECDI-SP④ ECDI-SP对移植物的保护依赖于MDSC Arakawa, et al [23] 2014 小鼠 胰岛 iNOS GM-CSF、IL-4、肝星状细胞 体外诱导分化MDSC，具有保护同种异体胰岛作用 Liao, et al[24] 2014 小鼠 皮肤 iNOS 地塞米松 糖皮质激素-糖皮质激素受体级联是地塞米松介导免疫抑制的关键 Nakamura, et al[25] 2015 小鼠 心脏 iNOS 西罗莫司 mTOR⑤、Raf/MEK/ERK信号通路在MDSC扩增中发挥重要作用 Gajardo, et al[26] 2015 小鼠 皮肤 iNOS和精氨酸酶 IL-33 IL-33诱导MDSC分化，减轻排斥反应 Nakamura, et al[27] 2016 小鼠 心脏 iNOS 西罗莫司 MDSC诱导移植物内Treg分化 Zhao, et al[28] 2018 小鼠 心脏 iNOS 地塞米松 地塞米松能够诱导MDSC在移植物内聚集 Nakao, et al[29] 2018 小鼠 心脏 iNOS 地塞米松 MDSC诱导Treg分化 注：①ILT2为免疫球蛋白样转录物2。
②—为未提及。
③IDO为吲哚胺2，3-双加氧酶。
④ECDI-SP为碳二亚胺偶联脾淋巴细胞。
⑤mTOR为哺乳动物雷帕霉素靶蛋白。
下载: 导出CSV
-
[1] FLEMING V, HU X, WEBER R, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression[J]. Front Immunol, 2018, 9: 398. DOI: 10.3389/fimmu.2018.00398. [2] ZHANG W, LI J, QI G, et al. Myeloid-derived suppressor cells in transplantation: the dawn of cell therapy[J]. J Transl Med, 2018, 16(1): 19. DOI: 10.1186/s12967-018-1395-9. [3] GARCIA AJ, RUSCETTI M, ARENZANA TL, et al. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression[J]. Mol Cell Biol, 2014, 34(11): 2017-2028. DOI: 10.1128/MCB.00090-14. [4] FUJⅡ W, ASHIHARA E, HIRAI H, et al. Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis[J]. J Immunol, 2013, 191(3): 1073-1081. DOI: 10.4049/jimmunol.1203535. [5] AARTS CEM, KUIJPERS TW. Neutrophils as myeloid-derived suppressor cells[J]. Eur J Clin Invest, 2018, 48 (Suppl 2): e12989. DOI: 10.1111/eci.12989. [6] HAILE LA, GAMREKELASHVILI J, MANNS MP, et al. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice[J]. J Immunol, 2010, 185(1): 203-210. DOI: 10.4049/jimmunol.0903573. [7] JITSCHIN R, BRAUN M, BÜTTNER M, et al. CLL-cells induce IDOhi CD14+HLA－DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote Tregs[J]. Blood, 2014, 124(5): 750-760. DOI: 10.1182/blood-2013-12-546416. [8] VASQUEZ-DUNDDEL D, PAN F, ZENG Q, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients[J]. J Clin Invest, 2013, 123(4): 1580-1589. doi: 10.1172/JCI60083 [9] GABRILOVICH DI, NAGARAJ S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol, 2009, 9(3): 162-174. DOI: 10.1038/nri2506. [10] LUAN Y, MOSHEIR E, MENON MC, et al. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion[J]. Am J Transplant, 2013, 13(12): 3123-3131. DOI: 10.1111/ajt.12461. [11] BRONTE V, BRANDAU S, CHEN SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards[J]. Nat Commun, 2016, 7: 12150. DOI: 10.1038/ncomms12150. [12] CONDAMINE T, MASTIO J, GABRILOVICH DI. Transcriptional regulation of myeloid-derived suppressor cells[J]. J Leukoc Biol, 2015, 98(6): 913-922. DOI: 10.1189/jlb.4RI0515-204R. [13] MARIGO I, BOSIO E, SOLITO S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor[J]. Immunity, 2010, 32(6): 790-802. DOI: 10.1016/j.immuni.2010.05.010. [14] HIGHFILL SL, RODRIGUEZ PC, ZHOU Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13[J]. Blood, 2010, 116(25): 5738-5747. DOI: 10.1182/blood-2010-06-287839. [15] LECHNER MG, LIEBERTZ DJ, EPSTEIN AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells[J]. J Immunol, 2010, 185(4): 2273-2284. DOI: 10.4049/jimmunol.1000901. [16] OBERMAJER N, KALINSKI P. Generation of myeloid-derived suppressor cells using prostaglandin E2[J]. Transplant Res, 2012, 1(1): 15. DOI: 10.1186/2047-1440-1-15. [17] DUGAST AS, HAUDEBOURG T, COULON F, et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion[J]. J Immunol, 2008, 180(12): 7898-7906. doi: 10.4049/jimmunol.180.12.7898 [18] ZHANG W, LIANG S, WU J, et al. Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts[J]. Transplantation, 2008, 86(8): 1125-1134. DOI: 10.1097/TP.0b013e318186fccd. [19] GARCIA MR, LEDGERWOOD L, YANG Y, et al. Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice[J]. J Clin Invest, 2010, 120(7): 2486-2496. DOI: 10.1172/JCI41628. [20] TURNQUIST HR, ZHAO Z, ROSBOROUGH BR, et al. IL-33 expands suppressive CD11b+ Gr-1int and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival[J]. J Immunol, 2011, 187(9): 4598-4610. DOI: 10.4049/jimmunol.1100519. [21] ADEEGBE D, SERAFINI P, BRONTE V, et al. In vivo induction of myeloid suppressor cells and CD4+Foxp3+ T regulatory cells prolongs skin allograft survival in mice[J]. Cell Transplant, 2011, 20(6): 941-954. DOI: 10.3727/096368910X540621. [22] CHEN G, KHERADMAND T, BRYANT J, et al. Intragraft CD11b+ IDO+ cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions[J]. Am J Transplant, 2012, 12(11): 2920-2929. DOI: 10.1111/j.1600-6143.2012.04203.x. [23] ARAKAWA Y, QIN J, CHOU HS, et al. Cotransplantation with myeloid-derived suppressor cells protects cell transplants: a crucial role of inducible nitric oxide synthase[J]. Transplantation, 2014, 97(7): 740-747. DOI: 10.1097/01.TP.0000442504.23885.f7. [24] LIAO J, WANG X, BI Y, et al. Dexamethasone potentiates myeloid-derived suppressor cell function in prolonging allograft survival through nitric oxide[J]. J Leukoc Biol, 2014, 96(5): 675-684. DOI: 10.1189/jlb.2HI1113-611RR. [25] NAKAMURA T, NAKAO T, YOSHIMURA N, et al. Rapamycin prolongs cardiac allograft survival in a mouse model by inducing myeloid-derived suppressor cells[J]. Am J Transplant, 2015, 15(9): 2364-2377. DOI: 10.1111/ajt.13276. [26] GAJARDO T, MORALES RA, CAMPOS-MORA M, et al. Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3+ regulatory T cells in skin-transplanted mice[J]. Immunology, 2015, 146(1): 81-88. DOI: 10.1111/imm.12483. [27] NAKAMURA T, NAKAO T, ASHIHARA E, et al. Myeloid-derived suppressor cells recruit CD4+/Foxp3+ regulatory T cells in a murine cardiac allograft[J]. Transplant Proc, 2016, 48(4): 1275-1278. DOI: 10.1016/j.transproceed.2015.10.060. [28] ZHAO Y, SHEN XF, CAO K, et al. Dexamethasone-induced myeloid-derived suppressor cells prolong allo cardiac graft survival through iNOS- and glucocorticoid receptor-dependent mechanism[J]. Front Immunol, 2018, 9: 282. DOI: 10.3389/fimmu.2018.00282. [29] NAKAO T, NAKAMURA T, MASUDA K, et al. Dexamethasone prolongs cardiac allograft survival in a murine model through myeloid-derived suppressor cells[J]. Transplant Proc, 2018, 50(1): 299-304. DOI: 10.1016/j.transproceed.2017.11.014. [30] SAVAGE TM, SHONTS BA, OBRADOVIC A, et al. Early expansion of donor-specific Tregs in tolerant kidney transplant recipients[J]. JCI Insight, 2018, 3(22):124086. DOI: 10.1172/jci.insight.124086. [31] HUANG B, PAN PY, LI Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host[J]. Cancer Res, 2006, 66(2): 1123-1131. doi: 10.1158-0008-5472.CAN-05-1299/ [32] KANG X, ZHANG X, LIU Z, et al. Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25－T cells by activation of the TGF-β/β-catenin pathway[J]. Mol Hum Reprod, 2016, 22(7): 499-511. DOI: 10.1093/molehr/gaw026. [33] PARK MJ, LEE SH, KIM EK, et al. Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice[J]. Sci Rep, 2018, 8(1): 3753. DOI: 10.1038/s41598-018-21856-2. [34] LEE CR, KWAK Y, YANG T, et al. Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-beta during murine colitis[J]. Cell Rep, 2016, 17(12): 3219-3232. DOI: 10.1016/j.celrep.2016.11.062. [35] OKANO S, ABU-ELMAGD K, KISH DD, et al. Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients[J]. Am J Transplant, 2018, 18(10): 2544-2558. DOI: 10.1111/ajt.14718. [36] KIM JI, LEE MK 4TH, MOORE DJ, et al. Regulatory T-cell counter-regulation by innate immunity is a barrier to transplantation tolerance[J]. Am J Transplant, 2009, 9(12): 2736-2744. DOI: 10.1111/j.1600-6143.2009.02847.x. [37] QIAN C, CAO X. Dendritic cells in the regulation of immunity and inflammation[J]. Semin Immunol, 2018, 35: 3-11. DOI: 10.1016/j.smim.2017.12.002. [38] MANNON RB. Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders?[J]. Curr Opin Organ Transplant, 2012, 17(1): 20-25. DOI: 10.1097/MOT.0b013e32834ee5b6. [39] PANG XL, WANG ZG, LIU L, et al. Immature dendritic cells derived exosomes promotes immune tolerance by regulating T cell differentiation in renal transplantation[J]. Aging (Albany NY), 2019, 11(20): 8911-8924. DOI: 10.18632/aging.102346. [40] TSE GH, HUGHES J. Macrophages and transplant rejection: a novel future target?[J]. Transplantation, 2013, 96(11): 946-948. DOI: 10.1097/TP.0b013e3182a4bf20. [41] ZAHORCHAK AF, MACEDO C, HAMM DE, et al. High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation[J]. Cell Immunol, 2018, 323: 9-18. DOI: 10.1016/j.cellimm.2017.08.008. [42] RIQUELME P, HAARER J, KAMMLER A, et al. TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity[J]. Nat Commun, 2018, 9(1): 2858. DOI: 10.1038/s41467-018-05167-8. [43] EVERLY MJ, EVERLY JJ, AREND LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss[J]. Am J Transplant, 2009, 9(5): 1063-1071. DOI: 10.1111/j.1600-6143.2009.02577.x. [44] GOODE I, XU H, ILDSTAD ST. Regulatory B cells: the new "it" cell[J]. Transplant Proc, 2014, 46(1): 3-8. DOI: 10.1016/j.transproceed.2013.08.075. [45] ÖZKAN B, LIM H, PARK SG. Immunomodulatory function of myeloid-derived suppressor cells during B cell-mediated immune responses[J]. Int J Mol Sci, 2018, 19(5):E1468. DOI: 10.3390/ijms19051468. [46] PARK MJ, LEE SH, KIM EK, et al. Myeloid-derived suppressor cells induce the expansion of regulatory B cells and ameliorate autoimmunity in the sanroque mouse model of systemic lupus erythematosus[J]. Arthritis Rheumatol, 2016, 68(11): 2717-2727. DOI: 10.1002/art.39767. [47] SHEN M, WANG J, YU W, et al. A novel MDSC-induced PD-1-PD-L1+ B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties[J]. Oncoimmunology, 2018, 7(4):e1413520. DOI: 10.1080/2162402X.2017.1413520. [48] GAZDIC M, SIMOVIC MARKOVIC B, VUCICEVIC L, et al. Mesenchymal stem cells protect from acute liver injury by attenuating hepatotoxicity of liver natural killer T cells in an inducible nitric oxide synthase- and indoleamine 2, 3-dioxygenase-dependent manner[J]. J Tissue Eng Regen Med, 2018, 12(2): e1173-e1185. DOI: 10.1002/term.2452. [49] XUE Q, YAN Y, ZHANG R, et al. Regulation of iNOS on immune cells and its role in diseases[J]. Int J Mol Sci, 2018, 19(12):E3805. DOI: 10.3390/ijms19123805. [50] CZYSTOWSKA-KUZMICZ M, SOSNOWSKA A, NOWIS D, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma[J]. Nat Commun, 2019, 10(1): 3000. DOI: 10.1038/s41467-019-10979-3. [51] NELP MT, KATES PA, HUNT JT, et al. Immune-modulating enzyme indoleamine 2, 3-dioxygenase is effectively inhibited by targeting its apo-form[J]. Proc Natl Acad Sci U S A, 2018, 115(13): 3249-3254. DOI: 10.1073/pnas.1719190115. [52] MOUGIAKAKOS D, JITSCHIN R, VON BAHR L, et al. Immunosuppressive CD14+HLA－DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation[J]. Leukemia, 2013, 27(2): 377-388. DOI: 10.1038/leu.2012.215. [53] MAEDA A, EGUCHI H, NAKAHATA K, et al. Monocytic MDSCs regulate macrophage-mediated xenogenic cytotoxicity[J]. Transpl Immunol, 2015, 33(2): 140-145. DOI: 10.1016/j.trim.2015.07.002. [54] WANG X, BI Y, XUE L, et al. The calcineurin-NFAT axis controls allograft immunity in myeloid-derived suppressor cells through reprogramming T cell differentiation[J]. Mol Cell Biol, 2015, 35(3): 598-609. DOI: 10.1128/MCB.01251-14.z [55] HOLMGAARD RB, ZAMARIN D, LI Y, et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner[J]. Cell Rep, 2015, 13(2): 412-424. DOI: 10.1016/j.celrep.2015.08.077. [56] SUN C, MEZZADRA R, SCHUMACHER TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3): 434-452. DOI: 10.1016/j.immuni.2018.03.014. [57] DENG L, LIANG H, BURNETTE B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124(2): 687-695. DOI: 10.1172/JCI67313. [58] GAO W, DEMIRCI G, STROM TB, et al. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival[J]. Transplantation, 2003, 76(6): 994-999. doi: 10.1097/01.TP.0000085010.39567.FB [59] LIGOCKI AJ, NIEDERKORN JY. Advances on non-CD4+ Foxp3+ T regulatory cells: CD8+, type 1, and double negative T regulatory cells in organ transplantation[J]. Transplantation, 2015, 99(8): 1553-1559.DOI: 10.1097/TP.0000000000000813. -
下载:
点击查看大图
图(2) / 表(1)
计量
- 文章访问数: 434
- HTML全文浏览量: 423
- PDF下载量: 37
- 被引次数: 0
